42 results
8-K
EX-99.1
DRMA
Dermata Therapeutics Inc
21 Mar 24
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
4:05pm
into the third quarter of 2024.
Research and development expenses were $4.1 million for the year ended December 31, 2023, compared to $5.7 million … for the year ended December 31, 2022. The decrease in research and development expense was the result of decreased clinical trial and non-clinical expenses
8-K
EX-99.1
gbtq8 jad5
9 Nov 23
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
1e1kwe np8c
10 Aug 23
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter
4:18pm
424B5
dma432q4xqnyp86x89r
25 May 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
b0hyw9itqyta8a
11 May 23
Dermata Therapeutics Provides Corporate Update and Reports First Quarter
4:07pm
S-3
xuy u609i1r3uc
15 Nov 22
Shelf registration
4:06pm
8-K
EX-99.1
x3brf43 cl
10 Nov 22
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
5:22pm
8-K
EX-99.1
b8vxvwt
15 Aug 22
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:20pm
DEF 14A
f4f3gmk i35v
1 Jun 22
Definitive proxy
4:20pm
PRE 14A
tqc3l
20 May 22
Preliminary proxy
4:05pm
424B3
50mykkrmsn2g jhsxhfb
19 May 22
Prospectus supplement
4:05pm